|
SKI expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.46790000044028E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.06130000016225E-07 |
| Normal-vs-Stage2 |
8.01939999961476E-07 |
| Normal-vs-Stage3 |
1.79850000003867E-07 |
| Normal-vs-Stage4 |
1.11790000001388E-06 |
| Stage1-vs-Stage2 |
4.953600E-01 |
| Stage1-vs-Stage3 |
4.359000E-01 |
| Stage1-vs-Stage4 |
7.421000E-01 |
| Stage2-vs-Stage3 |
9.368800E-01 |
| Stage2-vs-Stage4 |
7.699400E-01 |
| Stage3-vs-Stage4 |
8.100000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.47820000263278E-08 |
| Normal-vs-AfricanAmerican |
4.494300E-02 |
| Normal-vs-Asian |
2.793800E-04 |
| Caucasian-vs-AfricanAmerican |
9.240900E-03 |
| Caucasian-vs-Asian |
7.380100E-02 |
| AfricanAmerican-vs-Asian |
3.195000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.1470000000654E-07 |
| Normal-vs-Female |
1.59990000025978E-07 |
| Male-vs-Female |
9.268600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.99599999978406E-07 |
| Normal-vs-Age(41-60Yrs) |
3.29040000024428E-07 |
| Normal-vs-Age(61-80Yrs) |
2.37589999896315E-08 |
| Normal-vs-Age(81-100Yrs) |
6.720000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.722400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.685780E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.799000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.694790E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.713400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.822200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.743300E-03 |
| Classical-VS-Follicular |
2.175100E-04 |
| Classical-VS-Other |
2.050600E-01 |
| Classical-VS-Normal |
1.71922999999685E-05 |
| Tall-VS-Follicular |
7.265000E-01 |
| Tall-VS-Other |
8.232200E-01 |
| Tall-VS-Normal |
6.86769999758141E-08 |
| Follicular-VS-Other |
9.813400E-01 |
| Follicular-VS-Normal |
7.43329997554554E-09 |
| Other-VS-Normal |
9.416800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.09989999517313E-08 |
| Normal-vs-N1 |
2.89259999952662E-07 |
| N0-vs-N1 |
7.554800E-01 |
|
|
